Literature DB >> 32030416

Opportunistic infections after conversion to belatacept in kidney transplantation.

Dominique Bertrand1, Nathalie Chavarot2, Philippe Gatault3, Cyril Garrouste4, Nicolas Bouvier5, Anne Grall-Jezequel6, Maïté Jaureguy7, Sophie Caillard8, Mathilde Lemoine9, Charlotte Colosio10, Léonard Golbin11, Jean-Philippe Rerolle12, Antoine Thierry13, Johnny Sayegh14, Isabelle Etienne1, Ludivine Lebourg1, Rebecca Sberro2, Dominique Guerrot1.   

Abstract

BACKGROUND: Belatacept (bela) rescue therapy seems to be a valuable option for calcineurin inhibitor chronic toxicity in kidney transplantation. Nevertheless, the risk of infection associated with bela is not well reported.
METHODS: We report the rate of opportunistic infections (OPI) after a switch to bela in a multicentric cohort of 280 kidney transplant patients.
RESULTS: Forty-two OPI occurred in 34 patients (12.1%), on average 10.8 ± 11.3 months after the switch. With a cumulative exposure of 5128 months of bela treatment, we found an incidence of 0.008 OPI/month of exposure, and 9.8 OPI/100 person-years. The most common OPI was cytomegalovirus (CMV) disease in 18/42 OPI (42.9%) and pneumocystis pneumonia in 12/42 OPI (28.6%). Two patients presented a progressive multifocal leucoencephalopathy and two patients developed a cerebral Epstein-Barr virus-induced post-transplant lymphoproliferative disease. OPI led to death in 9/34 patients (26.5%) and graft failure in 4/34 patients (11.8%). In multivariate analysis, estimated glomerular filtration rate <25/mL/min/1.73 m2 on the day of the switch and the use of immunosuppressive agents before transplantation were associated with the occurrence of OPI. We found a higher rate of infection-related hospitalization (24.1 versus 12.3/100 person-years, P = 0.0007) and also a higher rate of OPI (13.2 versus 6.7/100 person-years, P = 0.005) in the early conversion group (within 6 months).
CONCLUSIONS: The risk of OPI is significant post-conversion to bela and may require additional monitoring and prophylactic therapy, particularly regarding pneumocystis pneumonia and CMV disease. These data need to be confirmed in a larger case-control study.
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  belatacept; infection; kidney transplantation

Mesh:

Substances:

Year:  2020        PMID: 32030416     DOI: 10.1093/ndt/gfz255

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  13 in total

1.  Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial.

Authors:  Klemens Budde; Rohini Prashar; Hermann Haller; María Rial; Nassim Kamar; Avinash Agarwal; Johan de Fijter; Lionel Rostaing; Stefan Berger; Arjang Djamali; Nicolae Leca; Lisa Allamassey; Sheng Gao; Martin Polinsky; Flavio Vincenti
Journal:  J Am Soc Nephrol       Date:  2021-10-27       Impact factor: 10.121

2.  Time-Limited Therapy with Belatacept in Kidney Transplant Recipients.

Authors:  Thibault Letellier; Delphine Kervella; Abderrahmane Sadek; Christophe Masset; Claire Garandeau; Cynthia Fourgeux; Victor Gourain; Jeremie Poschmann; Gilles Blancho; Simon Ville
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

3.  Successful use of azithromycin for Escherichia coli-associated renal allograft malakoplakia: a report of two cases.

Authors:  Paul M Kinsella; Olivia C Smibert; John B Whitlam; Mark Steven; Ricard Masia; Ronak G Gandhi; Camille N Kotton; Natasha E Holmes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-05-14       Impact factor: 3.267

4.  Identifying a Kidney Transplant Recipient COVID Phenotype to Aid Test Utilization in the Setting of Limited Testing Availability-Does One Exist?

Authors:  Sarthak Virmani; Shana E Gleeson; Gianna F Girone; Divyanshu Malhotra; Elizabeth A Cohen; Sharon E Klarman; William S Asch
Journal:  Transplant Proc       Date:  2020-06-20       Impact factor: 1.066

Review 5.  Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature.

Authors:  Pierre-Guillaume Deliège; Justine Bastien; Laetitia Mokri; Charlotte Guyot-Colosio; Carl Arndt; Philippe Rieu
Journal:  BMC Ophthalmol       Date:  2020-12-01       Impact factor: 2.209

6.  Converting Maintenance Kidney-Transplant Patients From Belatacept to Another Immunosuppressive Regimen: A Cautionary Tale.

Authors:  Sindhu Chandran; David Wojciechowski
Journal:  Kidney Int Rep       Date:  2020-11-05

7.  Hypomagnesemia Is a Risk Factor for Infections after Kidney Transplantation: A Retrospective Cohort Analysis.

Authors:  Balazs Odler; Andras T Deak; Gudrun Pregartner; Regina Riedl; Jasmin Bozic; Christian Trummer; Anna Prenner; Lukas Söllinger; Marcell Krall; Lukas Höflechner; Carina Hebesberger; Matias S Boxler; Andrea Berghold; Peter Schemmer; Stefan Pilz; Alexander R Rosenkranz
Journal:  Nutrients       Date:  2021-04-14       Impact factor: 5.717

8.  Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.

Authors:  Dominique Bertrand; Mouad Hamzaoui; Veronique Lemée; Julie Lamulle; Mélanie Hanoy; Charlotte Laurent; Ludivine Lebourg; Isabelle Etienne; Mathilde Lemoine; Frank Le Roy; Dorian Nezam; Jean-Christophe Plantier; Olivier Boyer; Dominique Guerrot; Sophie Candon
Journal:  J Am Soc Nephrol       Date:  2021-06-10       Impact factor: 14.978

9.  First case of COVID-19 in a kidney transplant recipient treated with belatacept.

Authors:  David Marx; Bruno Moulin; Samira Fafi-Kremer; Ilies Benotmane; Gabriela Gautier; Peggy Perrin; Sophie Caillard
Journal:  Am J Transplant       Date:  2020-04-28       Impact factor: 8.086

10.  Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.

Authors:  Ester Gallo; Isabella Abbasciano; Silvia Mingozzi; Antonio Lavacca; Roberto Presta; Stefania Bruno; Ilaria Deambrosis; Antonella Barreca; Renato Romagnoli; Alberto Mella; Fabrizio Fop; Luigi Biancone
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.